UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2017
ONCOMED PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-35993 | | 38-3572512 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
800 Chesapeake Drive
Redwood City, California 94063
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 995-8200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 1, 2017, OncoMed Pharmaceuticals, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”). At the 2017 Annual Meeting, the stockholders of the Company voted on the following proposals, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 13, 2017, as supplemented (the “Proxy Statement”):
Proposal 1: Election of Directors.
The stockholders elected the following individuals to the Company’s Board of Directors:
Nominee | | For | | Withheld | | Broker Non-Vote | | Uncast |
| | | | | | | | |
Perry A. Karsen | | 25,184,343 | | 453,016 | | 7,461,208 | | 0 |
Rick E Winningham | | 23,979,711 | | 1,657,648 | | 7,461,208 | | 0 |
Michael S. Wyzga | | 25,497,390 | | 139,969 | | 7,461,208 | | 0 |
| | | | | | | | |
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.
The stockholders ratified and approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.
For | | Against | | Abstain | | Broker Non-Vote | | Uncast |
32,887,128 | | 164,553 | | 46,886 | | 0 | | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
Date: June 5, 2017 | | | | ONCOMED PHARMACEUTICALS, INC. |
| | | |
| | | | By: | | /s/ Alicia J. Hager |
| | | | | | Alicia J. Hager, J.D., Ph.D. Senior Vice President and General Counsel |
